DYN Dyne Pharma: Company Short-Term Debts

Official company branding of Dyne Therapeutics (DYN)

Dyne Therapeutics, Inc. (DYN) is developing the innovative FORCE system for the delivery of RNA drugs to treat muscular dystrophies, attracting the attention of big pharma. The volume of short-term debt capital confirms its status as a pioneer in pathology therapy trusted by physicians. The value of 0.00 reflects the metric's balance, highlighting the company's reputational surge as a rising star in the orphan disease segment and a favorite among biotech investors.

Dyne Therapeutics (DYN) - Company Short-Term Loans and Borrowings from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Dyne Corp (DYN)

- current quotes and average value forecast:
Price Chart Dyne Therapeutics|DYN - Consensus Target
- company stock capitalization data:
Market Capitalization Dyne Therapeutics, Inc.|DYN - Enterprise Value
- business book valuation details:
Accounting Value per Share Dyne Therapeutics|DYN - Accounting Value of Company|Market Value to Book Value Ratio dyne-tx.com|DYN - Total Business Assets
- debt level and financial liquidity data:
Total Debt to Capital Dyne Therapeutics, Inc.|DYN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Dyne Therapeutics, Inc.|DYN - Company Aggregate Debts|Debt to Book Capitalization Ratio Dyne Therapeutics, Inc.|DYN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Dyne Therapeutics|Quick Liquidity dyne-tx.com
- earnings and valuation multiples indicators:
DYN - Company Net Income
Analysis of all company metrics:DYN - Dyne Therapeutics
Manufactured products of dyne-tx.com

The stability of Dyne Therapeutics, Inc. (DYN) is based on the diversification of the FORCE platform's clinical programs, which minimizes regulatory risks during drug development. This metric captures the total amount of obligations maturing within one year, determining liquidity and leverage efficiency; by analyzing the company's short-term liability structure, an investor can assess the business's actual margin of safety and the risk of potential default.

Competing companies

JAZZ - Company Short-Term Debt|Cytokinetics Inc. (CYTK) - Company Current Liabilities|PTCT: Company Short-Term Debts|Scholar Rock Inc. (SRRK) - Company Short-Term Debts|Company Current Liabilities CNTA|EWTX: Company Short-Term Loans and Borrowings|Company Short-Term Debt Rapport Therapeutics (RAPP)|Alumis Inc - Company Short-Term Indebtedness|Company Short-Term Debts ZVRA (Kempharm)|Contineum Corp (CTNM) - Short-Term Debt|LRMR: Company Current Liabilities|CAPR - Company Short-Term Debts|Entrada Therapeutics, Inc. (TRDA) - Company Short-Term Debt|Channel Therapeutics Inc. - Company Short-Term Loans and Borrowings|Company Short-Term Debt MediciNova Inc.|Short-Term Debt Serina Pharma SER|Company Short-Term Debt BioXcel Therapeutics (BTAI)|Company Short-Term Debt PMN (promisneurosciences.com)|Company Short-Term Debt Apimeds Pharmaceuticals US APUS|AEON Biopharma Inc. (AEON) - Short-Term Debt|NLS Pharma - Company Short-Term Debts|Short-Term Indebtedness Bionomics Limited (BNOX)|HUGE (FSD Pharma Inc.) - Company Current Liabilities|Short-Term Debt reatapharma.com (RETA)